Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Stentz

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Diabetes|July 19, 2013
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlatesRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Diabetes Care|September 25, 2013
Prediction of diabetes based on baseline metabolic characteristics in individuals at high riskRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Diabetes, Obesity & Metabolism|April 5, 2013
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trialG A Bray, S R Smith, M A Banerji, et al.
Age (Dordrecht, Netherlands)|September 3, 2016
Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose toleranceSara E Espinoza, Chen-Pin Wang, Devjit Tripathy, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 24, 2012
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factorsAramesh Saremi, Dawn C Schwenke, Thomas A Buchanan, et al.
The New England Journal of Medicine|March 25, 2011
Pioglitazone for diabetes prevention in impaired glucose toleranceRalph A DeFronzo, Devjit Tripathy, Dawn C Schwenke, et al.
The Journal of Clinical Endocrinology and Metabolism|January 21, 2015
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW studyDevjit Tripathy, Jeff E Cobb, Walter Gall, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Diabetes|July 19, 2013
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlatesRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Diabetes Care|September 25, 2013
Prediction of diabetes based on baseline metabolic characteristics in individuals at high riskRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Diabetes, Obesity & Metabolism|April 5, 2013
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trialG A Bray, S R Smith, M A Banerji, et al.
Age (Dordrecht, Netherlands)|September 3, 2016
Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose toleranceSara E Espinoza, Chen-Pin Wang, Devjit Tripathy, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 24, 2012
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factorsAramesh Saremi, Dawn C Schwenke, Thomas A Buchanan, et al.
The New England Journal of Medicine|March 25, 2011
Pioglitazone for diabetes prevention in impaired glucose toleranceRalph A DeFronzo, Devjit Tripathy, Dawn C Schwenke, et al.
The Journal of Clinical Endocrinology and Metabolism|January 21, 2015
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW studyDevjit Tripathy, Jeff E Cobb, Walter Gall, et al.
Pageof 5